Figure 1.

Representative glycosaminoglycan (GAG) map series derived from T1 maps measured on successive weeks. Initial GAG concentration ([GAG]) was substantially different for the two animals (one animal/series), and therefore each series is shown on its own color-scale. (A and C) Control [GAG] is stable (COV varied by ± 2–12%) throughout the recovery period for both series. (B and D) At the beginning of the recovery period (week 0), [GAG] for IL-1-exposed samples is lower than the initial [GAG] and steadily increases over the 3-week recovery period.